Holen Sie sich die Stockscreener-App
9.45
0.43%
0.04
Handel nachbörslich:
9.36
-0.09
-0.95%
Schlusskurs vom Vortag:
$9.41
Offen:
$9.38
24-Stunden-Volumen:
2.01M
Relative Volume:
1.67
Marktkapitalisierung:
$921.06M
Einnahmen:
$64.70M
Nettoeinkommen (Verlust:
$-123.43M
KGV:
-39.38
EPS:
-0.24
Netto-Cashflow:
$-95.23M
1W Leistung:
-0.63%
1M Leistung:
+247.43%
6M Leistung:
+256.60%
1J Leistung:
+193.48%
1-Tages-Spanne:
$9.36
$9.49
1-Wochen-Bereich:
$9.36
$9.555
52-Wochen-Spanne:
$1.87
$9.58
Poseida Therapeutics Inc Stock (PSTX) Company Profile
Firmenname
Poseida Therapeutics Inc
Sektor
Branche
Telefon
858-779-3100
Adresse
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Vergleichen Sie PSTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTX
Poseida Therapeutics Inc
|
9.45 | 921.06M | 64.70M | -123.43M | -95.23M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-08-04 | Eingeleitet | BofA Securities | Buy |
| 2020-08-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-04 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Poseida Therapeutics Inc Aktie (PSTX) Neueste Nachrichten
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Stock Position Lowered by Wellington Management Group LLP - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Sets New 52-Week HighHere's What Happened - MarketBeat
XTX Topco Ltd Increases Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Poseida Therapeutics executive chairman sells $283,866 in stock By Investing.com - Investing.com Canada
Poseida Therapeutics executive chairman sells $283,866 in stock - Investing.com
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - The Eastern Progress Online
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - The Eastern Progress Online
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges - Investing.com Nigeria
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges By Investing.com - Investing.com South Africa
Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show - Endpoints News
Poseida Therapeutics (NASDAQ:PSTX) Reaches New 1-Year HighStill a Buy? - MarketBeat
Poseida reports positive interim data on CAR-T therapies By Investing.com - Investing.com Canada
Roche: launch of takeover bid for Poseida Therapeutics - Marketscreener.com
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Roche commences tender offer for outstanding Poseida shares at $9 per share - TipRanks
Roche Launches $9/Share Cash Tender Offer for Poseida Therapeutics, CVR Could Add $4 More - StockTitan
Roche commences tender offer for all shares of Poseida - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders - Marketscreener.com
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - BioSpace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Poseida reports positive interim data on CAR-T therapies - Investing.com
Jacobs Levy Equity Management Inc. Sells 115,494 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics to Present at Upcoming Investor Conferences - Longview News-Journal
PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors - MSN
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting - The Eastern Progress Online
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc.PSTX - The Eastern Progress Online
Poseida Therapeutics (STU:2RZ) GF Value Rank : 1 (As of Dec. 04, 2024) - GuruFocus.com
Poseida Therapeutics stock soars to 52-week high of $9.43 By Investing.com - Investing.com Canada
Poseida Therapeutics stock soars to 52-week high of $9.43 - Investing.com
Roche to buy Poseida, building on CAR-T cell collaboration - Multiple Sclerosis News Today
Roche Agrees To Acquire Poseida Therapeutics - Contract Pharma
Roche Acquires Poseida for $1.5B - San Diego Business Journal
Big Pharma, big CGT deals: Roche buying Poseida, Novartis buys Kate - BioProcess Insider
Fred Alger Management LLC Buys Shares of 128,970 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis - Yahoo Finance
Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric - MSN
Roche to acquire Poseida Therapeutics for USD 1.5 billion - Medical Dialogues
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success - MSN
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet - MSN
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? - MSN
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - MSN
Poseida Therapeutics (FRA:2RZ) Degree of Operating Leverage : -0.28 (As of Sep. 2024) - GuruFocus.com
Bold Move by Roche: Pioneering the Future of Cell Therapy - substack.com
Finanzdaten der Poseida Therapeutics Inc-Aktie (PSTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Poseida Therapeutics Inc-Aktie (PSTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gergen Mark J | Executive Chairman |
Dec 10 '24 |
Sale |
9.46 |
30,000 |
283,866 |
651,291 |
| Gergen Mark J | Executive Chairman |
Nov 26 '24 |
Option Exercise |
2.78 |
30,000 |
83,430 |
681,291 |
| Gergen Mark J | Executive Chairman |
Nov 26 '24 |
Sale |
9.27 |
30,000 |
278,100 |
651,291 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):